A Phase Ib, Multi-center Study of Ningetinib(CT053PTSA) in Combination With Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative Who Have Progressed After EGFR TKI Treatment
Latest Information Update: 06 Jun 2024
At a glance
- Drugs Gefitinib (Primary) ; Ningetinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sunshine Lake Pharma
Most Recent Events
- 06 Jun 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified June 2022).
- 20 Jun 2022 Planned End Date changed from 17 Nov 2021 to 17 Jul 2023.
- 20 Jun 2022 Planned primary completion date changed from 17 Aug 2021 to 17 Jul 2023.